Galecto, Inc.

NasdaqCM GLTO

Galecto, Inc. Market Capitalization on January 14, 2025: USD 6.28 M

Galecto, Inc. Market Capitalization is USD 6.28 M on January 14, 2025, a -70.43% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Galecto, Inc. 52-week high Market Capitalization is USD 27.77 M on March 06, 2024, which is 342.02% above the current Market Capitalization.
Galecto, Inc. 52-week low Market Capitalization is USD 5.97 M on December 24, 2024, which is -4.93% below the current Market Capitalization.
Galecto, Inc. average Market Capitalization for the last 52 weeks is USD 16.34 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: GLTO

Galecto, Inc.

CEO	Dr. Hans T. Schambye M.D., Ph.D.
IPO Date	Oct. 29, 2020
Location	United States
Headquarters	75 State Street
Employees	13
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Key trends

Past 5 years